What is it about?
Statins are a cornerstone therapy with respect to lipid modification (achieving LDL -C treatment targets respectively to risk profile of the patient), however even more important due to their pleotrophic athrerosclerotic risk reduction. Ezetimibe is the recommended therapy added to statins in order to achieve this goals. In the light of new therapies (monoclonal antibodies -PCSK9 inchibitors), and their high cost, it is of ultimate importance to appropriate position this medications in the treatment of Hypercholesterolemic patients with CVD risk and/or CV disease, and in patients with familiar hypercholesterolemia.
Featured Image
Photo by timJ on Unsplash
Why is it important?
We highlited the rules for determining which hypolipemic medications options are available and there fore a viable option in patients with this this specific situations: high ASCVD hyperholesterolemic patients and patients with familiar hyperholesterolemia.
Perspectives
I hope this article will give clinicians a way of thinking, what is neceserry when new therapies are available and arriving. Because the way we spend money on health and social care is not just a problem for politicians, managers and researchers to worry about - it is an issue that touches every single human being on this planet in one way or another. More than anything else, and if nothing else, I hope you find this article thought-provoking.
Professor marija B Vavlukis
Ss' Cyril and Methodius University, in Skopje, Faculty of Medicine
Read the Original
This page is a summary of: Statins Alone or in Combination with Ezetimibe or PCSK9 Inhibitors in Atherosclerotic Cardiovascular Disease Protection, January 2019, IntechOpen,
DOI: 10.5772/intechopen.82520.
You can read the full text:
Contributors
The following have contributed to this page
